Single Patient Use of Selinexor and Dexamethasone for a Patient With Multiple Myeloma
NCT03850704 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS
Last updated 2019-02-22
Summary
This is an individual patient, expanded access protocol using Selinexor and dexamethasone ("Sd") for the treatment of Relapsed, Refractory multiple myeloma in a 64 year old male, "19023-UMN-01" weighing 105.7 kg. 19023-UMN-01 has IgG kappa myeloma that has relapsed after numerous treatments.
Conditions
Interventions
- DRUG
Sponsors & Collaborators
-
Masonic Cancer Center, University of Minnesota
lead OTHER
Principal Investigators
-
Erica Warlick, MD · Division of Hematology, Oncology and Transplantation, University of Minnesota
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
More Related Trials
-
Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma
NCT02186834 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma Patients
NCT04843579 ·Status: TERMINATED ·Phase: PHASE2
-
Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multiple Myeloma
NCT02628704 ·Status: WITHDRAWN ·Phase: PHASE2
-
Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma
NCT03110562 ·Status: COMPLETED ·Phase: PHASE3
-
Selinexor, Pomalidomide, and Dexamethasone For Multiple Myeloma With CNS Involvement
NCT05478993 ·Status: RECRUITING ·Phase: PHASE2
-
A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma
NCT07138209 ·Status: RECRUITING ·Phase: PHASE3
-
Study to Demonstrate Clinical Benefit of Lenalidomide and Dexamethasone
NCT03809780 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.
NCT04414475 ·Status: RECRUITING ·Phase: PHASE2
-
Real-World Use of Selinexor, Daratumumab and Dexamethasone in Chinese Patients With Multiple Myeloma at First Relapse
NCT05559788 ·Status: UNKNOWN
-
Selinexor and Backbone Treatments of Multiple Myeloma Patients
NCT02343042 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma
NCT04782687 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma
NCT04756401 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma
NCT05530421 ·Status: RECRUITING ·Phase: PHASE2
-
A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed Refractory Multiple Myeloma
NCT03944057 ·Status: COMPLETED ·Phase: PHASE2
-
Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma
NCT04925193 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
NCT00424047 ·Status: COMPLETED ·Phase: PHASE3
-
Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy.
NCT04519476 ·Status: RECRUITING ·Phase: PHASE1
-
Elotuzumab, Selinexor, and Dexamethasone for Relapsed Refractory Multiple Myeloma
NCT05170789 ·Status: WITHDRAWN ·Phase: PHASE2
-
Selinexor in Combination With Immunomodulator （Thalidomide/Pomalidomide/Lenalidomide）in RRMM
NCT04941937 ·Status: RECRUITING ·Phase: PHASE2
-
MLN9708 and Dexamethasone for High-Risk Smoldering Multiple Myeloma
NCT01660997 ·Status: WITHDRAWN ·Phase: PHASE2
-
Lenalidomide/Low-dose Dexamethasone in Combination With Continuous Oral Cyclophosphamide Compared to Lenalidomide/Low-dose Dexamethasone Combined With Single Cyclophosphamide Doses IV in Patients With Relapsed/Refractory Multiple Myeloma
NCT01019174 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)
NCT03374085 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients With Relapsed or Relapsed and Refractory Multiple Myeloma
NCT00378209 ·Status: COMPLETED ·Phase: PHASE2
-
Selinexor in Combination With Thalidomide and Dexamethasone in RRMM
NCT04891744 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
NCT00056160 ·Status: COMPLETED ·Phase: PHASE3